lanthanum carbonate (La2[CO3]3, Fosrenol)
Jump to navigation
Jump to search
Introduction
Tradename: Fosrenol
Indications
- reduction of serum phosphorus in patient with end-stage renal disease
Contraindications
Dosage
- start 760-1500 mg QD in divided doses
- increase as needed at 2 week intvervals in 750 mg increments
- most patients require* 1500-3000 mg QD
Tabs: 250 & 500 mg (elemental lanthunum)
* requirement assessed by serum phosphate < 6 mg/dL
Adverse effects
- nausea/vomiting 10%
- dialysis graft occlusion 8%
- abdominal pain 8%
Mechanism of action
- La+2-containing phosphate-binder
More general terms
Components
References
- ↑ Prescriber's Letter 11(12): 2004 New Drug: Lanthanum Carbonate (Fosrenol) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201209&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ http://www.fosrenol.com